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REPORT
PLA2G6 Mutation Underlies Infantile Neuroaxonal Dystrophy
Shareef Khateeb,* Hagit Flusser,* Rivka Oﬁr, Ilan Shelef, Ginat Narkis, Gideon Vardi, Zamir Shorer,
Rachel Levy, Aharon Galil, Khalil Elbedour, and Ohad S. Birk
Infantile neuroaxonal dystrophy (INAD) is an autosomal recessive progressive neurodegenerative disease that presents
within the ﬁrst 2 years of life and culminates in death by age 10 years. Affected individuals from two unrelated Bedouin
Israeli kindreds were studied. Brain imaging demonstrated diffuse cerebellar atrophy and abnormal iron deposition in
the medial and lateral globus pallidum. Progressive white-matter disease and reduction of the N-acetyl aspartate:chro-
mium ratio were evident onmagnetic resonance spectroscopy, suggesting loss ofmyelination. The clinical and radiological
diagnosis of INAD was veriﬁed by sural nerve biopsy. The disease gene was mapped to a 1.17-Mb locus on chromosome
22q13.1 (LOD score 4.7 at recombination fraction 0 for SNP rs139897), and an underlying mutation common to both
affected families was identiﬁed in PLA2G6, the gene encoding phospholipase A2 group VI (cytosolic, calcium-indepen-
dent). These ﬁndings highlight a role of phospholipase in neurodegenerative disorders.
From the Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben-Gurion
University (S.K.; R.O.; G.N.; O.S.B.), Zusman Child Development Center (H.F.; G.V.; A.G.), and the Neuroradiology Unit (I.S.), Pediatric Neurology Unit
(Z.S.), Infectious Diseases Laboratory (R.L.), and Genetics Institute (K.E.; O.S.B.), Soroka Medical Center, Beer-Sheva, Israel
Received June 30, 2006; accepted for publication August 16, 2006; electronically published September 19, 2006.
Address for correspondence and reprints: Dr. Ohad Birk, Genetics Institute, Soroka University Medical Center, Beer-Sheva, 84101 Israel. E-mail:
obirk@bgu.ac.il
* These authors contributed equally to this work.
Am. J. Hum. Genet. 2006;79:942–948.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7905-0016$15.00
Infantile neuroaxonal dystrophy (INAD) (MIM 256600) is
a neurodegenerative disease characterized by pathologic
axonal swelling and spheroid bodies in the CNS.1 Onset
is within the ﬁrst 2 years of life, and the disease culminates
in death by age 10 years. Most patients with INAD show
a progressive disorder with motor and mental deteriora-
tion, cerebellar ataxia, marked hypotonia of the trunk
with later bilateral pyramidal tract signs, spastic tetraple-
gia, hyperreﬂexia, and early visual disturbances. Seizures
are not reported. Electroencephalography shows charac-
teristic high-voltage fast rhythms, with electromyography
results consistent with chronic denervation. All patients
have abnormal visual evoked potentials.2,3 T2-weighted
magnetic resonance imaging (MRI) typically shows cere-
bellar atrophy with signal hyperintensity in the cerebellar
cortex and, occasionally, hypointensity in the pallida and
substantia nigra.4 Pathological hallmarks are marked neu-
roaxonal dystrophy, severe cerebellar atrophy, and degen-
eration of the lateral corticospinal tracts. Axonal endings
show spheroid bodies, often detectable in the skin and
conjunctivae.
The similar disorder pantothenate kinase-associated
neurodegeneration (PKAN), also known as “Hallervorden-
Spatz disease,” has overlapping clinical and pathologic
features and is caused by mutations in the PANK2 gene
(MIM *606157; GenBank accession number NM_153640).5
PKAN is described as an extrapyramidal syndrome with
dystonia and choreoathetosis. In PKAN, the pattern of
iron accumulation in the basal ganglia is unique and re-
sults in a characteristic “tiger eye” sign on brain MRI: a
combination of high signal intensity in the center of the
globus pallidum and low signal intensity in the surround-
ing region.6 This tiger eye phenomenon is typically absent
in INAD. PKAN usually has a late-infantile or juvenile age
at onset, with patients typically surviving into their 3rd
decade.5 It is noteworthy that early-onset cases of PKAN
and late-onset cases of INAD have been reported.5 Linkage
analysis andmolecular analysis5 excluded the PANK2 gene
as causative in eight patients with INAD from seven
families,1,4 indicating that INAD and PKAN are genetically
distinct disorders.
Another disease to be considered in the differential di-
agnosis of INAD is Schindler disease type I, which is caused
by mutations in a-N-acetylgalactosaminidase (NAGA).
The resulting NAGA deﬁciency is a rare lysosomal storage
disorder presenting as INAD with severe psychomotor re-
tardation, myoclonic seizures, decorticate posture, optic
atrophy, blindness, marked long-tract signs, and total loss
of contact with the environment by age 3–4 years.7 Char-
acteristic “spheroids” are observed histologically and ul-
trastructurally in terminal axons in gray matter. MRI of
the brain shows diffuse white-matter abnormalities with
a secondary, symmetrical demyelination. Diagnosis is
achieved through urinary oligosaccharide measurements
and enzymatic assays of NAGA activity in leukocytes or
ﬁbroblasts.8
Here, in a study done independently of and in parallel
to that by Morgan et al.,9 we report the identiﬁcation of
a homozygous mutation in PLA2G6 (MIM *603604), the
gene encoding phospholipase A2 (PLA2) group VI (cyto-
solic, calcium-independent [Entrez Protein accession
number NP_003551.2]), as being associated with INAD in
two Israeli Bedouin families. Two consanguineous inbred
Israeli Bedouin kindred presented with a similar, appar-
ently autosomal recessive, severe progressive neurodegen-
erative phenotype affecting a total of 8 individuals (ﬁg.
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Figure 1. Pedigrees of the investigated families. A, Kindred 1, in which 5 affected individuals and 15 unaffected individuals were
available for genetic analysis. B, Kindred 2, in which one affected individual and two parents were available for genetic analysis. A
high rate of consanguinity and an autosomal recessive pattern of inheritance can be observed.
1). Of the 8 patients, 6 were available for detailed clinical
and molecular analyses. The study was approved by the
Soroka University Medical Center Institutional Review
Board and by the Israel National Helsinki Committee in
Genetics, and informed consent was obtained from all
individuals tested. Affected individuals were free of symp-
toms at birth, achieved milestones such as initial walking
and speaking several words, presented at age 10–18 mo
with regression in cognitive and motor abilities, and pro-
gressed to a vegetative state by age 4 years and death at
age 7–10 years. Clinical hallmarks were hypotonia of the
trunk with enhanced tonus in the limbs (spastic quadri-
plegia), augmented tendon reﬂexes, and symmetric py-
ramidal tract signs. Combined vertical and horizontal nys-
tagmus and pallor of the optic discs were evident. There
was no dysmorphism and no defects or phenotypic stig-
mata other than the neurological phenotype.
Of the 8 affected individuals, 6 had undergone CT or
MRI studies, all showing the radiological hallmarks of
INAD—namely, severe cerebellar atrophy and hypoin-
tensity in the pallida (suggestive of iron accumulation).
Figure 2 shows index patients (from each of the two kin-
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Figure 2. MRI studies. Patient X1:2 is shown at age 3 years (A and B) and, in a follow-up study, at age 9 years (C–H). A, PD-weighted
brain MRI showing early atrophy of the cerebellum, with prominent folia and fourth ventricle. B, T2-weighted brain MRI of the
supratentorial region is unremarkable; there are no signs of iron deposition in the globus pallidum. C–E, PD-, T2*-, and T2-weighted
brain MRI, respectively, showing the development of iron deposition in the medial and lateral parts of the globus pallidum, as well as
signiﬁcant brain atrophy. Note absence of the tiger eye sign. F–H, T1-, T2-, and PD-weighted brain MRI, respectively, showing abnormal
signal, in the medial part of the putamen, that was not present at an earlier age. Brain MRI of patient IV:4 is shown at age 2 years
(I–L). I, T2-weighted brain MRI showing severe atrophy of the cerebellum, with very prominent folia and fourth ventricle. J–L, T2-,
T2*-, and PD-weighted brain MRI, respectively, at the level of the basal ganglia, showing normal signal intensity of the globus pallidum
and putamen, with no evidence of brain atrophy. M, MRS (echo time ms) of the white matter of patient X1:2 at age 9[TE]p 144
years, showing conversion of the normal pattern of NAA:Cr and NAA:Cho ratio to signiﬁcant reduction of NAA. N, MRS of the brain
(TE p 144 ms) of patient X1:2 at age 3 years, showing normal ratio of NAA to Cho and Cr.
dreds) who were subject, at various ages, to repeated MRI
studies that showed a consistent pattern of progression of
the radiological ﬁndings: at early stages, the sole ﬁndings
were of cerebellar atrophy, which progressed with age.
Later, they developed progressive disease of the whitemat-
ter. Magnetic resonance spectroscopy (MRS) depicts the
chemical composition of tissues on the basis of differences
in resonance frequencies of tissue metabolites. In affected
individuals, MRS of the white matter showed conversion
of the normal pattern of the N-acetyl aspartate (NAA):
chromium (Cr) and NAA:choline compounds (Cho) ratios
(ﬁg. 2N) to signiﬁcant reduction of NAA, suggesting loss
of myelinization (ﬁg. 2M). Abnormal signals in the globus
pallidum were noted as low signals on T2-, T2*-, and pro-
ton density (PD)–weighted images, suggestive of iron ac-
cumulation. It should be noted that the abnormal signals
were seen in both the medial and lateral portions of the
globus pallidum. Tiger eye sign was not seen on any of
theMRI studies. Abnormal hyperintense signals on T2 and
ﬂuid attenuated inversion recovery sequences were seen
www.ajhg.org The American Journal of Human Genetics Volume 79 November 2006 945
in the medial aspect of the putamen, most probably as
part of a degenerative process.
The results of metabolic tests were all within normal
limits. These tests includedmeasurements of hepatic func-
tion, renal function, thyroid function, creatine phos-
phokinase, lactate, pyruvate, ammonia, carnitine (total
and free), very long-chain fatty acids, urinary oligosac-
charides, urinary organic acids, and blood and urinary
amino acids. Transferrin electrophoresis (for carbohy-
drate-deﬁcient glycoprotein syndrome) and karyotypes
were also normal; speciﬁc enzymatic assays in affected
individuals ruled out Krabbe disease, metachromatic leu-
kodystrophy, and NAGA deﬁciency.
Whereas results of rectal and skin biopsies were normal,
electron-microscopy analysis of sural nerve biopsy was
consistent with INAD, with axons showing spheroid bod-
ies. Results of muscle biopsies (gastrocnemius) were nor-
mal. It should be noted that spheroids are not expected
to be seen in all biopsy specimens from patients with
INAD.9
On the basis of the consanguinity of the families stud-
ied, we assumed a founder effect in the affected families.
Affected individuals were shown to not be homozygous
at the PANK2 locus, which ruled out PKAN (data not
shown). Genomewide linkage analysis with the use of 400
polymorphic markers (ABI PRISM Linkage Mapping Set
MD10 [Applied Biosystems]) was conducted with ﬁve af-
fected individuals of kindred 1. The individuals tested
were X:1, X:6, XI:1, XI:2, and X:15, depicted in ﬁgure 1A.
None of the 400 polymorphic markers tested showed ho-
mozygosity in all ﬁve affected individuals. For four mark-
ers, four of ﬁve individuals were homozygous. However,
ﬁnemapping of those regions inDNA samples of 20 family
members ruled out linkage to those loci (data not shown).
We then proceeded to perform a genomewide linkage
analysis of the same ﬁve patients and two obligatory car-
riers (parents of affected individuals), using the Affymetrix
10K SNP arrays. In all ﬁve individuals, 226 loci exhibited
homozygosity. Of those loci, we selected ﬁve candidate
loci on the basis of two criteria: the region of homozy-
gosity was informative (homozygous in the affected in-
dividuals and heterozygous in the obligatory carriers) and
was 12 Mb. Fine mapping of these ﬁve loci—by testing
the 20 available DNA samples of kindred 1 with the use
of polymorphic markers—ruled out linkage to four of the
ﬁve loci (data not shown). The ﬁfth locus, on chromosome
22q13.1 (harboring SNPs rs763668 and rs139897), was
bordered by recombination events in affected individuals
at adjacent SNPs rs132692 and rs926299, implying a ho-
mozygosity region of 2.58 Mb (ﬁg. 3). Figure 3 shows that
ﬁne mapping of this locus in all available 20 DNA samples
of kindred 1 deﬁned a 1.17-Mb locus between TR1_C and
TR4_272 as being associated with the disease (LOD score
4.82 at for SNP rs139897, calculated using SUPER-vp 0
LINK10; TR1_C and TR4_272 are polymorphic markers de-
signed using TandemRepeats Finder11 [sequences available
on request]). It is interesting to note that, of the 10,000
SNPs assayed, only 2 adjacent ones in the deﬁned locus
were homozygous in all ﬁve affected individuals tested.
The limited size of the homozygosity locus common to
the affected family members demonstrates the advantages
of high-density SNP arrays and explains why genomewide
linkage analysis that used 400 polymorphic markers failed
to identify the disease-associated locus.
Sequencing of the coding region of 24 of the 37 genes
within the 22q13.1 locus revealed no mutations (data not
shown). As shown in ﬁgure 4, sequence analysis of
PLA2G6 (GenBank accession number NM_003560.2) re-
vealed a 2070_2072delTGT mutation in exon 15, which
resulted in the deletion of valine at position 691 (V691del)
of the encoded protein, PLA2 group VI (cytosolic, calcium-
independent). An identical mutation was found in the
affected individuals in kindred 2 (ﬁg. 1). Denaturing high-
pressure liquid chromatography (dHPLC) analysis of the
entire two kindreds was compatible with the mutation
being associated with the disease phenotype, implying full
penetrance (data not shown; PCR primer sequences, am-
pliﬁcation procedures used for sequencing, and dHPLC
details are available on request). The mutation, in a het-
erozygous form, was found in only a single individual of
300 unrelated Bedouin controls tested by dHPLC analysis.
Interestingly, both affected families and the unrelated car-
rier had the same haplotype surrounding the mutation.
Further, in an independent study9 done in parallel to this
study, the same PLA2G6 mutation was also reported in
two patients unrelated to each other or to the families
described here, which corroborates its associationwith the
disease phenotype.
On the basis of these ﬁndings and those from the study
by Morgan et al.,9 which demonstrated several other
PLA2G6 mutations in INAD, molecular diagnosis of INAD
can, at least in part, replace the invasive biopsies used in
the diagnosis of this disease thus far. Moreover, carrier
detection and prenatal diagnosis in affected families is
made possible. In fact, we have already made molecular
prenatal and presymptomatic diagnoses in two healthy
siblings of affected individuals.
The function of the PLA2 enzymes is to catalyze the
release of fatty acids from phospholipids. They display,
therefore, a suite of physiological functions, including
phospholipid remodeling, arachidonic acid release, leu-
kotriene and prostaglandin synthesis, Fas-mediated apo-
ptosis, and transmembrane ion ﬂux in glucose-stimulated
B-cells.13 The full-length PLA2G6 cDNA encodes an 806-
aa protein with a lipase motif and seven ankyrin re-
peats.14,15 The human and rodent homologues of this pro-
tein share 90% amino acid sequence identity, with the
human sequence differing in that it contains a 54-aa res-
idue insertion that would interrupt the last putative an-
kyrin repeat. Five splice variants of the human gene are
known to exist.14 Two of the alternatively spliced forms
encode only the ankyrin repeat region of the protein. The
three others also harbor the lipasemotif (GXSXG).16 Figure
4 demonstrates that V691 of PLA2 group VI (cytosolic,
Figure 3. Fine mapping of the 22q13.1 locus in kindred 1. A, Disease-associated haplotype is boxed. Minimal homozygosity locus
associated with the disease is deﬁned between the markers TR1_C and TR4_272 (region between the red lines). Sequences of TR1_C and
TR4_272 are available on request. B, Schematic presentation of the deﬁned locus. Markers TR5_1177, TR1_B, TR1_C, TR1_A, TR1_1045,
TR_9, TR_7, TR_8, TR2_2045 and TR4_272 were designed using Tandem Repeats Finder.10 Primer sequences are available on request.
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Figure 4. Mutation analysis of the 2070_2072delTGT mutation in exon 15 of PLA2G6. Sequence analysis is shown for an unaffected
individual (A), an obligatory carrier (B), and an affected individual (C). D, ClustalW sequence alignment of human PLA2 group VI
(cytosolic, calcium-independent) to orthologues. The V691del (boxed) of this protein is highly conserved throughout evolution. Conserved
residues are indicated with asterisks. E, Deleted valine residing within a putative calmodulin-binding site of this phospholipase. Schematic
is adapted from Jenkins et al.12
calcium-independent), which is deleted in our patients, is
extremely well conserved throughout evolution and re-
sides within immediate proximity to a putative calmo-
dulin-binding site of the phospholipase12,17 (ﬁg. 4E). This
putative calmodulin-binding motif exists in only two of
the three lipase motif–containing splice variants.12 Cal-
modulin is known to inhibit activity of PLA2.12,17 A pos-
sible effect, if any, of themutation on calmodulinbinding,
either enhancing or diminishing its inhibitory effect on
the phospholipase activity, is yet to be demonstrated.
However, a parallel study by Morgan et al.9 suggests that
PLA2G6 mutations causing INAD are likely to result in
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loss of function. It is interesting to note that, in the adult
rat brain (speciﬁcally including the cerebellum), the ac-
tivity levels of PLA2 group VI (cytosolic, calcium-inde-
pendent) are signiﬁcantly higher than those of other PLA2
family members (i.e., cPLA2-IV, sPLA2-IIA, and sPLA2-V).18
Moreover, the activity of this enzyme in the rat brain is
signiﬁcantly augmented in the ﬁrst few weeks of life,
reaching a near plateau at age 10 wk.12 These facts are in
line with the human PLA2G6 mutation causing the in-
fantile-onset brain phenotype of INAD.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Entrez Protein, http://www.ncbi.nlm.nih.gov/entrez/query
.fcgi?dbpProtein (for PLA2 group VI, cytosolic, calcium-inde-
pendent [accession number NP_003551.2])
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for PANK2
cDNA [accession number NM _153640] and PLA2G6 cDNA [ac-
cession number NM_003560.2])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for INAD, PANK2, and PLA2G6)
Tandem Repeats Finder, http://tandem.bu.edu/trf/trf.html
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